Speaker
Description
Aim
Evidence on organized mammography breast cancer screening (BCS) reflects mainly overall effects. We aim to estimate age-specific breast cancer mortality reductions attributable to BCS.
Methods
This population-based difference-in-differences study paired countries by similarity and screening initiation. The earlier-initiating country served as the screening country and the later-initiating country as the control. Pairs with significantly different pre-screening mortality trends (p ≤ 0.05) were excluded. Age-specific effects were estimated by comparing mortality changes between corresponding cohorts in each pair. The assumed log-linear coverage–effect relationship was evaluated using mean absolute error (MAE) and mean absolute percentage error (MAPE). Overall population-level effects were obtained by aggregating age-specific reductions using standard population weights.
Results
The UK–Ireland and Hungary–Poland pairs were eligible, with the UK and Hungary serving as screening countries. In the UK–Ireland pair (64% coverage), reductions increased with age from 9.6% (95% CI, −0.8% to 18.9%) at ages 55–59 to 38.9% (32.1%–45.0%) at ages 65–69, remaining substantial through age 79. Similar patterns were observed in Hungary–Poland (45% coverage). After rescaling coverage to 45%, modeled reductions from UK-Ireland closely matched observed reductions in Hungary–Poland (MAE, 0.017; MAPE, 6.1%). Modeled overall mortality reductions increased from 15.9% (95% CI, 10.9%–20.5%) at 45% coverage to 21.8% (15.1%–28.0%) at 64% and 31.9% (22.5%–40.1%) at 100%.
Conclusion
Breast cancer screening effectiveness depended primarily on coverage and lifetime screening duration. Age-specific estimates may inform assessments of progress toward the WHO Global Breast Cancer Initiative target.